Chapter Member Anniversaries: January 2024

Posted by ISPE Boston
On January 5, 2024

Please congratulate the following members celebrating milestone anniversaries in January 2024. Their dedication to ISPE, the Boston Area Chapter and the industry is applauded! Over Twenty Years Michael L. Anderson, FST Technical Services LLC Daniel E. Baxter, Vertex Pharmaceuticals Incorporated Robert G. Beane, Jr., Barry-Wehmiller Design Group Dr. Anthony C. Bevilacqua, Ph.D., Mettler-Toledo Thornton Inc […]

Welcome New Members December 2023!

Posted by ISPE Boston
On January 5, 2024

We would like to introduce the Members who joined ISPE in December 2023, welcome them to the Chapter and encourage them (and all our members) to take advantage of the many professional development, networking and information resources available through ISPE. Fellow ISPE members are a terrific resource for help with everyday professional challenges. And the […]

BMS Acquires Karuna in $14 Billion Deal

Posted by ISPE Boston
On January 4, 2024

Bristol Myers Squibb has agreed to acquire Boston-based biopharma Karuna Therapeutics for $330 per share in a transaction valued at $14 billion. Karuna is focused on therapies for psychiatric and neurological conditions with a lead asset called KarXT, an antipsychotic with a novel mechanism of action and differentiated efficacy and safety. Karuna’s NDA for KarXT […]

Tome Biosciences Launches, Acquires California Biotech

Posted by ISPE Boston
On January 4, 2024

Watertown-based Tome Biosciences launched in mid-December 2023 with $213 million in Series A and B funding from investors and moved to acquire California biotech Replace Therapeutics just two weeks later. Tome promises “to usher in a new era of genomic medicines based on programmable genomic integration (PGI).” PGI enables the insertion of any DNA sequence, […]

Fun at EDEI December Social!

Posted by ISPE Boston
On December 21, 2023

The Ethnocultural Diversity, Equity, and Inclusion (EDEI) Committee hosted a social on Thursday, December 7th at the Maharaja Restaurant in Cambridge, MA. Trivia on Indian diversity in the pharma world and Tambola (an Indian version of Bingo) were played as the restaurant served delicious Indian food. Everyone had a special time learning about various aspects […]

AstraZeneca to Acquire Vaccine Maker Icosavax in $1.1 Billion Deal

Posted by ISPE Boston
On December 20, 2023

AstraZeneca has announced plans to acquire Seattle-based Icosavax, a clinical-stage biopharm focused on developing vaccines using a protein virus-like particle (VLP) platform. The proposed acquisition, valued at up to $1.1 billion, will build on AstraZeneca’s expertise in respiratory syncytial virus (RSV), strengthening AstraZeneca’s late-stage pipeline with Icosavax’s lead investigational vaccine candidate, IVX-A12, a potential first-in-class, […]

Moderna and Merck Combined Therapy Cuts Melanoma Recurrence in Half

Posted by ISPE Boston
On December 20, 2023

Moderna and Merck have announced follow-up data from the Phase 2b clinical trial evaluating Moderna’s investigational INT (individualized neoantigen therapy) mRNA-4157 (V940) in combination with Merck’s Keytruda in patients with high-risk melanoma (Stage III/IV) following surgery. Treatment with the combination therapy reduced the risk of recurrence or death by 49% and the risk of developing […]

Calling Volunteers!

Posted by ISPE Boston
On December 20, 2023

Are you passionate about our events and eager to participate more frequently? How about attending them for free? We’re on the lookout for one to two volunteers for each of our events. Volunteer responsibilities include setting up materials, assisting with registrations, providing directions, and occasionally participating in taste tests! If this sounds like an exciting […]

Posted by ISPE Boston
On December 14, 2023

Vertex Pharmaceuticals and CRISPR Therapeutics have announced that the FDA has approved their CRISPR/Cas9 genome-edited cell therapy, to be marketed as Casgevy, for the treatment of sickle cell disease (SCD) in patients 12 years and older. This approval means that for the first time, approximately 16,000 patients with SCD may be eligible for a durable […]

FDA Approves bluebird bio Gene Therapy for Sickle Cell Disease

Posted by ISPE Boston
On December 14, 2023

bluebird bio has announced FDA approval for the gene therapy Lyfgenia for the treatment of sickle cell disease. The therapy has been approved for patients ages 12 and older who suffer from debilitating pain crises due to the condition. The FDA action is the second such approval in as many days, the first belonging to […]

Page 15 of 118«‹13 141516 17 ›»